NASDAQ: HYPDHyperion Defi Inc Stock
$5.67-0.25 (-4.22%)
Updated Nov 6, 2025
HYPD Price
$5.67
Fair Value Price
N/A
Market Cap
$32.29M
52 Week Low
$0.85
52 Week High
$41.06
P/E
-0.19x
P/B
0.86x
P/S
821.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$44.44k
Earnings
-$40.02M
Gross Margin
-7,177.3%
Operating Margin
-85,006.99%
Profit Margin
-90,270.2%
Debt to Equity
0.49
Operating Cash Flow
-$20M
Beta
1.17
Next Earnings
Nov 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HYPD Overview
A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HYPD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HYPD
Ranked#359 of 481
Ranked#359 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.33 | A | |
| $105.20 | A | |
| $134.05 | A |
Be the first to know about important HYPD news, forecast changes, insider trades & much more!
HYPD News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HYPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HYPD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HYPD is good value based on its book value relative to its share price (0.86x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
HYPD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HYPD due diligence checks available for Premium users.
Valuation
HYPD fair value
Fair Value of HYPD stock based on Discounted Cash Flow (DCF)
Price
$5.67
Fair Value
-$11.34
Undervalued by
150.01%
HYPD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HYPD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
252.41x
Market
45.67x
HYPD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
4.85x
HYPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HYPD's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.7M
Profit Margin
0%
HYPD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HYPD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$55.7M
Liabilities
$18.3M
Debt to equity
0.49
HYPD's short-term liabilities ($10.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HYPD's short-term assets ($9.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HYPD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HYPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$45.5M
Financing
$52.6M
HYPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HYPD vs Biotech Stocks
Hyperion Defi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.